Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-based differences in long-term mortality after TAVR among patients with bicuspid aortic valve.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Fate of dilated ascending aorta after transcatheter aortic valve replacement.

JTCVS structural and endovascular·2026
Same author

On-Scene, Residential Extracorporeal Cardiopulmonary Resuscitation for Refractory Out-of-Hospital Cardiac Arrest: Operational and Logistical Considerations.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Hemodynamic-guided V-A ECMO management for cardiogenic shock: Insight from initial experience from TWEET study (to wean an ECMO trials).

Perfusion·2026
Same author

Left Ventricular Venting Strategies for Cardiogenic Shock in Patients Treated With Extracorporeal Cardiopulmonary Support V-A ECMO: From Left Ventricular Unloading to Offloading.

The American journal of cardiology·2026
Same author

Clinical Significance of Interatrial Septal Thickening: A Retrospective Study.

Echocardiography (Mount Kisco, N.Y.)·2026

Related Experiment Video

Updated: Jul 14, 2026

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
06:52

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Sirolimus-induced alveolar hemorrhage.

Wissam I Khalife1, Polonca Kogoj, Biswajit Kar

  • 1Department of Cardiology, Division of Heart Failure/Cardiac Transplantation, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA. wkhalife@yahoo.com

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|June 5, 2007
PubMed
Summary

Sirolimus, an immunosuppressant, can cause rare but severe lung damage like diffuse alveolar hemorrhage. Promptly stopping sirolimus can lead to recovery, highlighting the need for vigilance in transplant patients.

More Related Videos

Rodent Inferior Vena Cava Venoplasty Balloon Model
05:44

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 14, 2026

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
06:52

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Rodent Inferior Vena Cava Venoplasty Balloon Model
05:44

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Sirolimus is a crucial immunosuppressant in solid-organ transplantation.
  • While effective, sirolimus carries risks, including rare pulmonary toxicity.
  • Pulmonary complications necessitate careful patient monitoring.

Observation:

  • A case of sirolimus-induced diffuse alveolar hemorrhage is presented.
  • Diagnosis was confirmed via bronchoscopy after excluding other causes.
  • Symptoms resolved rapidly after sirolimus cessation.

Findings:

  • Sirolimus can precipitate diffuse alveolar hemorrhage, a serious adverse event.
  • Bronchoscopic evidence and clinical resolution support sirolimus as the etiology.
  • Early recognition and drug withdrawal are key to patient recovery.

Implications:

  • Clinicians should consider sirolimus-induced pulmonary toxicity in transplant recipients with unexplained respiratory symptoms.
  • This adverse effect underscores the importance of a thorough differential diagnosis in immunosuppressed patients.
  • Awareness of this rare complication can improve patient outcomes and guide treatment strategies.